Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Belumosudil in Indian Participants With Chronic Graft-versus-host Disease
NCT07135973Phase 4Not yet recruiting
- Sponsor
- Sanofi
- Start
- Oct 2026
- Primary completion
- Aug 2027
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of belumosudil in chronic graft-versus-host disease (cGVHD), sponsored by Sanofi. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
belumosudil
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT07135973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07135973.